Functionalizing AuNPs with peptides or antibodies specific to lung cancer biomarkers, such as epidermal growth factor receptor (EGFR), enables targeted therapy that lowers off-target effects while improving therapeutic outcomes [370]. This evidence concerns the gene EGFR and lung cancer.